Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.32% is 94% below its 5-year average of 22.88%, near the low end of its 5-year range (0.15%–54.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 105.15% above its 12-month average of 0.64%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.32%.
DEBT TO ASSETS RATIO
1.32%
DEBT TO ASSETS RATIO AVG TTM
0.64%
DEBT TO ASSETS RATIO AVG 3Y
15.42%
DEBT TO ASSETS RATIO AVG 5Y
22.88%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+105.15%
CURRENT VS 3Y AVG
-91.45%
CURRENT VS 5Y AVG
-94.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+1363.59%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$259.14M
Debt to Assets Ratio
1.32%
TTM Avg
0.64%
3Y Avg
15.42%
5Y Avg
22.88%
Market Cap
$259.12M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.49M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.56M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.63M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.27M
Debt to Assets Ratio
0.31%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$255.88M
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $259.14M | 1.32% | 0.64% | 15.42% | 22.88% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.03% | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 0.40% | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 0.03% | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 0.00% | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 0.31% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.47M | 0.03% | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 0.13% | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 0.55% | N/A | N/A | N/A |
Debt/Assets
1.3%
Debt/Equity
0.01
Current Ratio
16.00
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.32% |
| 2026-03-31 | 1.38% |
| 2025-12-31 | 0.18% |
| 2025-09-30 | 0.18% |
| 2025-06-30 | 0.15% |
| 2025-03-31 | 0.18% |
| 2024-12-31 | 0.21% |
| 2024-09-30 | 0.90% |
| 2024-06-30 | 18.66% |
| 2024-03-31 | 26.09% |
| 2023-12-31 | 51.57% |
| 2023-09-30 | 44.87% |
| 2023-06-30 | 54.71% |
| 2023-03-31 | 54.43% |
| 2022-12-31 | 46.99% |
| 2022-09-30 | 32.72% |
| 2022-06-30 | 27.04% |
| 2022-03-31 | 36.18% |
| 2021-12-31 | 32.00% |
| 2021-09-30 | 26.87% |
| 2021-06-30 | 23.80% |
| 2021-03-31 | 19.37% |
| 2020-12-31 | 878.42% |
| 2020-09-30 | 1372.65% |
| 2019-12-31 | 363.38% |
